Provention Bio, Inc.
(NASDAQ : PRVB)

( )
PRVB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.53%35.180.9%$1221.11m
JNJJohnson & Johnson
0.68%132.250.7%$898.76m
MRKMerck & Co., Inc.
1.31%86.170.6%$797.92m
BMYBristol-Myers Squibb Company
1.02%47.461.4%$680.93m
ABBVAbbVie, Inc.
3.23%66.512.3%$635.12m
LLYEli Lilly and Company
1.81%112.521.0%$459.39m
NVSNovartis AG Sponsored ADR
0.01%89.480.2%$184.97m
AZNAstraZeneca PLC Sponsored ADR
0.19%44.431.2%$164.25m
GSKGlaxoSmithKline plc Sponsored ADR
0.46%40.380.3%$97.17m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.87%51.210.1%$78.17m
SNYSanofi Sponsored ADR
1.69%42.730.2%$51.63m
LCILannett Company, Inc.
2.07%6.9136.6%$11.34m
AKTXAkari Therapeutics Plc Sponsored ADR
-0.52%1.931.6%$3.82m
EPIXESSA Pharma Inc
20.53%1.820.1%$0.04m

Company Profile

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.